CD163 and breast carcinoma: Finally, in order to investigate the potential of CD163 to predict survival from the initial breast cancer diagnosis (PT diagnosis) we next compared survival (MFI plus OS from time of MBC diagnosis) in patients with high or low levels of CD163+ immune cells in the tumor nest, tumor stroma, or of CD163 GEX in the PT (Fig. 5A) or synchronous LNM (Fig. 5B).